...
机译:临床生成风险模型预测一线免疫细胞疗法后滤泡淋巴瘤的早期进展
Univ Munich Univ Hosp Dept Med 3 Munich Germany;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
Robert Bosch Krankenhaus Dept Clin Pathol Stuttgart Germany;
Univ Hosp Schleswig Holstein Hematopathol Sect Campus Kiel Kiel Germany;
Robert Bosch Krankenhaus Dept Clin Pathol Stuttgart Germany;
Univ Munich Univ Hosp Dept Med 3 Munich Germany;
Univ Wurzburg Inst Pathol Wurzburg Germany;
Robert Bosch Krankenhaus Dept Clin Pathol Stuttgart Germany;
Univ Hosp Schleswig Holstein Hematopathol Sect Campus Kiel Kiel Germany;
Mem Sloan Kettering Canc Ctr Dept Med 1275 York Ave New York NY 10021 USA;
Univ Rochester Wilmot Canc Inst Rochester NY USA;
Univ Rochester Wilmot Canc Inst Rochester NY USA;
Mayo Clin Div Hematol Rochester MN USA;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
Univ Munich Univ Hosp Dept Med 3 Munich Germany;
Univ Munich Univ Hosp Dept Med 3 Munich Germany;
Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;
Univ Munich Univ Hosp Dept Med 3 Munich Germany;
机译:临床生成风险模型预测一线免疫细胞疗法后滤泡淋巴瘤的早期进展
机译:基线宠物衍生的代谢肿瘤体积度量并未预测在第III期镓研究中用一线免疫化治疗和抗体维持治疗的滤泡淋巴瘤患者的结果
机译:PRIMA试验一线免疫放疗后组织学改变的滤泡性淋巴瘤患者的危险因素和结果
机译:鉴定卵腔淋巴瘤患者总生存的基因重要性
机译:新型免疫疗法和化学疗法对滤泡性和弥漫性大B细胞淋巴瘤的疗效
机译:临床遗传风险模型预测一线免疫化学疗法后滤泡性淋巴瘤的早期进展
机译:PRIMA试验对一线免疫化学疗法反应后发生组织学改变的滤泡性淋巴瘤患者的危险因素和结果